Notice: This company has been marked as potentially delisted and may not be actively trading. Intensity Therapeutics, Inc. Common stock (INTS) News Today Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesOwnershipShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Intensity Therapeutics files to sell 1.24M shares of common stock for holdersDecember 14, 2024 | markets.businessinsider.comIntensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS)December 12, 2024 | prnewswire.comPromising Clinical Progress and Financial Stability Drive Positive Outlook for Intensity Therapeutics, Inc.November 22, 2024 | markets.businessinsider.comIntensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private PlacementNovember 21, 2024 | prnewswire.comIntensity Therapeutics presents INT230-6 Phase 1/2 daya in SarcomaNovember 18, 2024 | markets.businessinsider.comIntensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)November 18, 2024 | prnewswire.comIntensity Therapeutics Inc.: Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 16, 2024 | finanznachrichten.deIntensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 13, 2024 | prnewswire.comIntensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) MeetingNovember 8, 2024 | prnewswire.comHC Wainwright & Co. Initiates Coverage of Intensity Therapeutics (INTS) with Buy RecommendationNovember 1, 2024 | msn.comIntensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22)October 31, 2024 | prnewswire.comIntensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 4, 2024 | prnewswire.comIntensity Therapeutics, Inc. (INTS)August 15, 2024 | finance.yahoo.comIntensity Therapeutics Inc.: Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 9, 2024 | finanznachrichten.deIntensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 8, 2024 | prnewswire.comIntensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue SarcomaJuly 9, 2024 | prnewswire.comIntensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of DirectorsMay 15, 2024 | prnewswire.comIntensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug CandidateMay 10, 2024 | prnewswire.comIntensity Therapeutics Inc.: Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 10, 2024 | finanznachrichten.deINTS Stock Earnings: Intensity Therapeutics Reported Results for Q1 2024May 10, 2024 | msn.comIntensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 9, 2024 | prnewswire.comIntensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024April 2, 2024 | finance.yahoo.comOutlook Therapeutics Inc.March 18, 2024 | wsj.comIntensity Therapeutics Inc.: Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate UpdateMarch 15, 2024 | finanznachrichten.deIntensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate UpdateMarch 14, 2024 | finance.yahoo.comIntensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024March 14, 2024 | prnewswire.comIntensity Therapeutics to Present at the 2024 BIO CEO & Investor ConferenceFebruary 21, 2024 | finance.yahoo.comIntensity Therapeutics to Present at the 2024 BIO CEO & Investor ConferenceFebruary 21, 2024 | prnewswire.comIntensity Therapeutics Unveils New Incentive Compensation PlanFebruary 8, 2024 | msn.comPerspective Therapeutics prices stock offering of $60.0M and $20.8M private placementJanuary 18, 2024 | msn.comINTS Intensity Therapeutics, Inc.January 11, 2024 | seekingalpha.comIntensity Therapeutics Inc.: Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma ProgramJanuary 3, 2024 | finanznachrichten.deIntensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma ProgramJanuary 3, 2024 | finance.yahoo.comIntensity Therapeutics (NASDAQ:INTS) Is In A Good Position To Deliver On Growth PlansDecember 29, 2023 | finance.yahoo.comIntensity Therapeutics Inc INTSDecember 27, 2023 | morningstar.comCheckpoint stock plunges 50% on FDA rejection of skin cancer drugDecember 18, 2023 | msn.comTrading was temporarily halted for "INTS" at 03:12 PM with a stated reason of "LULD pause."December 15, 2023 | marketbeat.comIntensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial OfficerDecember 12, 2023 | finance.yahoo.comIntensity Therapeutics to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate UpdateDecember 11, 2023 | finance.yahoo.comIntensity Therapeutics Reports Second Quarter Financial Results and Provides Corporate UpdateDecember 11, 2023 | finance.yahoo.comIntensity Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceDecember 11, 2023 | finance.yahoo.comIntensity Therapeutics Receives Orphan Drug Designation for the three key ingredients in INT230-6 for the Treatment of Soft Tissue SarcomaDecember 11, 2023 | finance.yahoo.comIntensity Therapeutics Presents Positive INT230-6 Data in Patients with Refractory Soft Tissue Sarcoma at the Connective Tissue Oncology Society Annual Meeting 2023December 11, 2023 | finance.yahoo.comIntensity Therapeutics Reports Third Quarter Financial Results and Provides Corporate UpdateDecember 11, 2023 | finance.yahoo.comIntensity Therapeutics Selected for Spotlight Oral Presentation at the 2023 San Antonio Breast Cancer SymposiumDecember 11, 2023 | finance.yahoo.comIntensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCSDecember 11, 2023 | finance.yahoo.comTrading was temporarily halted for "INTS" at 02:12 PM with a stated reason of "LULD pause."December 8, 2023 | marketbeat.comTrading was temporarily halted for "INTS" at 11:12 AM with a stated reason of "LULD pause." Trading set to resume at 11:12 AM. December 8, 2023 | marketbeat.comTrading was temporarily halted for "INTS" at 09:12 AM with a stated reason of "LULD pause."December 5, 2023 | marketbeat.comTrading was temporarily halted for "INTS" at 11:12 AM with a stated reason of "LULD pause."December 4, 2023 | marketbeat.com Get Intensity Therapeutics, Inc. Common stock News Delivered to You Automatically Sign up to receive the latest news and ratings for INTS and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s Sending THIS Crypto Higher on Purpose (Ad)Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW INTS Media Mentions By Week INTS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. INTS News Sentiment▼1.890.60▲Average Medical News Sentiment INTS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. INTS Articles This Week▼00▲INTS Articles Average Week Get Intensity Therapeutics, Inc. Common stock News Delivered to You Automatically Sign up to receive the latest news and ratings for INTS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies XFOR News Today INMB News Today ADVM News Today CRDL News Today IPSC News Today GNTA News Today HLVX News Today SCLX News Today CLLS News Today QNCX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:INTS) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intensity Therapeutics, Inc. Common stock Please log in to your account or sign up in order to add this asset to your watchlist. Share Intensity Therapeutics, Inc. Common stock With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
